


Contents lists available at [ScienceDirect](http://ScienceDirect.com)

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid

Medical Imagery


Cystic lung lesions revealing a *Pneumocystis jirovecii* and *Aspergillus flavus* co-infection in an HIV-infected patient

Figure 1. Chest X-ray showing diffuse alveolo-interstitial infiltrates (A), and computed tomography (B and C) showing diffuse cystic lesions (asterisks) surrounded by ground-glass opacities (arrow), and sometimes with thicker walls, mimicking an 'air crescent sign' (arrowhead).

An untreated, HIV-infected, 39-year-old woman presented with a dry cough of 1-month duration. The physical examination was normal. A chest X-ray showed diffuse alveolo-interstitial infiltrates predominantly in the lung apex (Figure 1A). A computed tomography (CT) scan disclosed diffuse cystic lesions surrounded by ground-glass opacities (Figure 1B, C). Some cavitory lesions presented thicker walls, mimicking an 'air crescent sign'. The patient's CD4 count was 83 cells/ μ l and HIV viral load was 501 180 copies/ml. Bronchoalveolar lavage (BAL) fluid examination revealed 360 000 cells/ml, including macrophages (66%), neutrophils (32%), and eosinophils (2%), with foamy exudates suggestive of *Pneumocystis pneumonia* (PCP). Mycological findings confirmed *Pneumocystis jirovecii* cysts and trophic forms, associated with filamentous elements with culture of *Aspergillus flavus*. Galactomannan antigen was detected in serum and BAL fluid. Of note, there was no additional predisposing factor for invasive aspergillosis, in particular no neutropenia or corticosteroid therapy.¹ Co-trimoxazole was administrated at a curative dose for 21 days, followed by secondary prophylaxis. Highly-active antiretroviral therapy was started 10 days later. The probable pulmonary invasive aspergillosis was treated with voriconazole for 3 months. The patient's clinical condition improved rapidly.

Follow-up CT showed progression towards nodular non-cavitory lesions at 6 weeks, and normalized at 3 months.

Cystic PCP is an unrecognized condition, although involving more than 30% of patients in some series.^{2,3} These excavations may enhance the risk of *Aspergillus* co-infection, rarely described in HIV-infected patients.^{1,4,5}

Ethical approval: Not required.

Conflict of interest: No conflict of interest to declare.

References

1. Lortholary O, Meyohas MC, Dupont B, Cadranet J, Salmon-Ceron D, Peyramond D, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. *Am J Med* 1993;**95**:177–87.
2. Kuhlman JE, Kavuru M, Fishman EK, Siegelman SS. *Pneumocystis carinii* pneumonia: spectrum of parenchymal CT findings. *Radiology* 1990;**175**:711–4.
3. Chow C, Templeton PA, White CS. Lung cysts associated with *Pneumocystis carinii* pneumonia: radiographic characteristics, natural history, and complications. *Am J Roentgenol* 1993;**161**:527–31.
4. Ponces Bento D, Esteves F, Matos O, Miranda AC, Ventura F, Araújo C, et al. Unusual coexistence of opportunistic lung infections in a human immunodeficiency virus positive patient suffering from persistent *Pneumocystis jirovecii* pneumonia: a case report. *Rev Port Pneumol* 2013;**19**:129–33.

<http://dx.doi.org/10.1016/j.ijid.2015.06.021>

1201-9712/© 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

5. Shankar EM, Kumarasamy N, Rajan R, Balakrishnan P, Solomon S, Devaleenol B, et al. *Aspergillus fumigatus*, *Pneumocystis jiroveci*, *Klebsiella pneumoniae* and *Mycoplasma fermentans* co-infection in a HIV infected patient with respiratory conditions from southern India. *Indian J Med Res* 2006;**123**:181–4.

Marie-Elodie Langlois^a

Marjorie Lorillou^b

Tristan Ferry^{a,c}

Christian Chidiac^{a,c}

Florent Valour^{a,c,*}

^aDepartment of Infectious Diseases, Hospices Civils de Lyon,
103 Grande Rue de la Croix-Rousse, 69004 Lyon, France

^bDepartment of Pneumology, Hospices Civils de Lyon, Lyon, France

^cINSERM U1111, International Centre for Research in Infectiology,
Claude Bernard Lyon 1 University, Lyon, France

*Corresponding author. Tel.: +33 4 72 07 11 07

Received 19 May 2015

Received in revised form 19 June 2015

Accepted 25 June 2015

Corresponding Editor: Eskild Petersen, Aarhus, Denmark